Junshi Biotech announced that due to fund terms and liquidity arrangements, Shanghai Tanying, a shareholder holding 5% or more of its shares, and LVC Fund, the total shareholding ratio dropped from 6.94% to 5.96% from June 16 to August 10, 2026, and changes in equity hit the 1% scale. Among them, Shanghai Tanying reduced its holdings by 1.04 million shares through bulk transactions, falling from 5.41% to 4.43%. The shareholding ratio of the other two parties remained unchanged. This change in equity will not result in changes in controlling shareholders and actual controllers.

Junshi Biotech announced that due to fund terms and liquidity arrangements, Shanghai Tanying, a shareholder holding 5% or more of its shares, and LVC Fund, the total shareholding ratio dropped from 6.94% to 5.96% from June 16 to August 10, 2026, and changes in equity hit the 1% scale. Among them, Shanghai Tanying reduced its holdings by 1.04 million shares through bulk transactions, falling from 5.41% to 4.43%. The shareholding ratio of the other two parties remained unchanged. This change in equity will not result in changes in controlling shareholders and actual controllers.